These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16279094

  • 1. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
    Stepanova EV, Bokhian BIu, Petrovichev NN, Lichinitzer MR.
    Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
    [Abstract] [Full Text] [Related]

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 3. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
    Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL.
    Cancer Chemother Pharmacol; 2004 May; 53(5):409-14. PubMed ID: 15132128
    [Abstract] [Full Text] [Related]

  • 4. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Häusler P, Becker H, Liersch T.
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [Abstract] [Full Text] [Related]

  • 5. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K, Khan K, Yu SZ, Ronson S, Rhee J, Li G, Van Echo D, Suntharalingam M, O'Malley BW, Li D.
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [Abstract] [Full Text] [Related]

  • 6. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH.
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [Abstract] [Full Text] [Related]

  • 7. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW, Hashmi S, Bell D, Diasio RB.
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [Abstract] [Full Text] [Related]

  • 8. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    Uchida K, Danenberg PV, Danenberg KD, Grem JL.
    BMC Cancer; 2008 Dec 23; 8():386. PubMed ID: 19105824
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB.
    Cancer J; 2007 Dec 23; 13(4):247-56. PubMed ID: 17762760
    [Abstract] [Full Text] [Related]

  • 10. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Boskos CS, Liacos C, Korkolis D, Aygerinos K, Lamproglou I, Terpos E, Stoupa E, Baltatzis G, Beroukas K, Papasavvas P, Dimopoulos MA, Bamias A.
    J Surg Oncol; 2010 Oct 01; 102(5):408-12. PubMed ID: 19877119
    [Abstract] [Full Text] [Related]

  • 11. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV.
    Clin Cancer Res; 2000 Apr 01; 6(4):1322-7. PubMed ID: 10778957
    [Abstract] [Full Text] [Related]

  • 12. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
    Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Hölscher AH, Danenberg PV, Brabender J.
    Clin Lung Cancer; 2010 Sep 01; 11(5):328-34. PubMed ID: 20837458
    [Abstract] [Full Text] [Related]

  • 13. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H, Clinical Study Group of Capecitabine.
    Anticancer Drugs; 2008 Sep 01; 19(8):819-24. PubMed ID: 18690094
    [Abstract] [Full Text] [Related]

  • 14. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R.
    Pharmacogenet Genomics; 2006 Nov 01; 16(11):809-16. PubMed ID: 17047489
    [Abstract] [Full Text] [Related]

  • 15. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
    Honda J, Sasa M, Moriya T, Bando Y, Hirose T, Takahashi M, Nagao T, Tangoku A.
    J Med Invest; 2008 Feb 01; 55(1-2):54-60. PubMed ID: 18319546
    [Abstract] [Full Text] [Related]

  • 16. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N, Gynecologic Oncology Group.
    Gynecol Oncol; 2005 Mar 01; 96(3):810-7. PubMed ID: 15721430
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ.
    Eur J Cancer; 2009 Jul 01; 45(11):1999-2006. PubMed ID: 19457654
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C, Liersch T, Meyer W, Baretton GB, Schwabe W, Häusler P, Kulle B, Becker H, Aust DE.
    Am J Surg Pathol; 2006 Sep 01; 30(9):1169-74. PubMed ID: 16931962
    [Abstract] [Full Text] [Related]

  • 20. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A, Danenberg PV.
    Int J Oncol; 2007 Aug 01; 31(2):413-8. PubMed ID: 17611699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.